Helix BioPharma Corp. stock is experiencing notable volatility as it navigates recent financial results and market conditions.
This week, Helix BioPharma Corp. (HBP.TO) has seen its shares fluctuate, closing at C$0.92, up 2.22% on Friday but down 3.16% over the past week. The company continues to face challenges as it operates in a difficult capital markets environment for small-cap biotech firms.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$70.27M
52W high
$3.00
52W low
$0.85
1W change
-3.16%
Beta
-0.14
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 171.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+171.7% Upside
Current Price
C$0.92
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
109.6%
Annualized
90-Day Vol
76.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.77
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.87 | C$0.59 – C$1.27 |
| 60 trading days | C$0.82 | C$0.48 – C$1.39 |
| 90 trading days | C$0.77 | C$0.40 – C$1.48 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Helix BioPharma navigates a challenging landscape marked by recent financial disclosures and a lack of major news catalysts. The stock's performance remains under pressure, with a significant year-to-date decline of 61.67%.
C$0.92 closing price reflects a 2.22% gain on Friday.
Despite the recent uptick, Helix BioPharma's stock is down 3.16% for the week and has plunged nearly 49% over the last month.
Bull case
Analysts are cautiously optimistic, with an average target price of C$2.50, indicating a potential upside of 171.7% from current levels. This optimism may be due to the company's ongoing development efforts in the biotech sector.
Bear case
The recent performance of Helix BioPharma highlights broader struggles in the biotech space, with a year-to-date drop of 61.67% and a profit margin of 0.0%. Investors should be aware of the volatility and risks associated with small-cap biotech stocks.
Recent Price Action
Advertisement
Helix BioPharma Corp. has experienced a modest gain of 2.22% on Friday, closing at C$0.92. However, the stock has faced a 3.16% decline over the past week and a staggering 48.89% drop in the last month. Year-to-date, the stock has plummeted 61.67%, indicating a challenging environment for the company.
Company News and Headlines
This week did not bring any major news for Helix BioPharma Corp. However, the company's financial results released earlier in the year revealed a challenging capital markets environment for small-cap biotech firms. The financial disclosures reflect ongoing struggles, including a reported net loss of $5,205,000 for the fiscal year ending July 31, 2025. Investors may want to keep a close eye on future announcements and updates from the company.
Technical Picture
Analyzing the technical indicators, Helix BioPharma's stock is currently trading well below its 50-day moving average of C$1.53 and its 200-day moving average of C$1.74, showing declines of 39.9% and 47.1% respectively. The stock has a 52-week range of C$0.85 to C$3.00, with the current price at just 3% of this range. The beta of -0.14 indicates lower volatility compared to the market, but the recent trading volume of 3,823 shares is significantly below the 20-day average volume of 17,173 shares, suggesting reduced investor interest.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
